Nykredit A S Acquires New Position in Teva Pharmaceutical Industries Ltd. $TEVA

Nykredit A S acquired a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 443,442 shares of the company’s stock, valued at approximately $15,024,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TEVA. Norges Bank bought a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $1,098,060,000. WCM Investment Management LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the first quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after acquiring an additional 26,813,522 shares during the period. Wellington Management Group LLP grew its position in shares of Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after purchasing an additional 6,878,304 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after purchasing an additional 5,917,423 shares during the period. Finally, Schroder Investment Management Group lifted its holdings in Teva Pharmaceutical Industries by 261.1% during the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after purchasing an additional 5,370,253 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Eliyahu Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the completion of the sale, the executive vice president directly owned 65,621 shares in the company, valued at $2,237,676.10. The trade was a 61.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $36.36 on Friday. The stock’s 50-day simple moving average is $34.64 and its two-hundred day simple moving average is $33.28. Teva Pharmaceutical Industries Ltd. has a twelve month low of $18.21 and a twelve month high of $38.37. The firm has a market capitalization of $42.37 billion, a P/E ratio of 60.60, a P/E/G ratio of 4.57 and a beta of 0.87. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The firm had revenue of $4.14 billion during the quarter. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. UBS Group lifted their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.89.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: S&P Global Ratings upgraded Teva’s long-term issuer rating to BBB- from BB+ with a stable outlook. Combined with recent Fitch and Moody’s upgrades, Teva now has investment-grade ratings from all major agencies, potentially lowering borrowing costs and improving flexibility to invest in growth. S&P Global Ratings upgrades Teva
• Positive Sentiment: UBS raised its price target on TEVA to $48 from $42 and maintained a Buy rating, citing potential upside from the company’s improved financial profile and growth strategy.
• Positive Sentiment: Teva reported positive Phase IIa results for its anti-IL-15 therapy TEV ’408 in celiac disease. The treatment met the study goal of preventing gluten-induced intestinal damage and showed a favorable safety profile, strengthening the late-stage pipeline. TEV ’408 celiac disease study
• Neutral Sentiment: Teva agreed to act as stalking-horse bidder for substantially all BioXcel Therapeutics assets in a Chapter 11 auction, offering up to $125 million in cash plus assumed liabilities. The deal could expand Teva’s at-home treatment opportunity, but the final purchase price and assets acquired remain uncertain. Teva-backed BioXcel bid
• Neutral Sentiment: Teva is advancing a plan to exchange its ordinary shares for American Depositary Shares on the NYSE, which could simplify trading and broaden access for U.S. investors, although the immediate earnings impact is limited. Teva NYSE listing update
• Negative Sentiment: Reported insider activity has been heavily weighted toward selling, with no insider purchases and 14 sales over the past six months. This may temper investor enthusiasm, though insider sales can reflect compensation or portfolio decisions rather than deteriorating fundamentals.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.